pyrazines has been researched along with 2-piperidone in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Salchner, P; Singewald, N | 1 |
| Brnjic, S; D'Arcy, P; De Cesare, M; Fryknäs, M; Hassan, M; Larsson, R; Linder, S; Lindsten, K; Olofsson, MH; Perego, P; Sadeghi, B | 1 |
| Amerik, AY; Issaenko, OA | 1 |
| Chung, CH; Jang, HC; Kim, JA; Kim, SW; Lee, WY; Min, KW; Nam-Goong, IS; Rhee, EJ; Shivane, VK; Sosale, AR | 1 |
| Brnjic, S; D'Arcy, P; Fryknäs, M; Larsson, R; Linder, S; Mazurkiewicz, M; Sun, C; Zhang, X | 1 |
| Anderson, KC; Carrasco, RD; Chauhan, D; D'Arcy, P; Hu, Y; Linder, S; Ray, A; Richardson, P; Tai, YT; Tian, Z; Wang, X | 1 |
| Anchoori, RK; Chen, X; Hung, CF; Jiang, R; Karanam, B; Matsui, W; Orlowski, RZ; Peng, S; Roden, RB; Rudek, MA; Tanno, T; Walters, KJ; Wang, JW; Zhao, M | 1 |
| Bahekar, R; Jadav, P; Jain, M; Joharapurkar, A; Patel, D; Sairam, KV; Shah, SR; Singh, PK | 1 |
| Athyros, VG; Elisaf, MS; Filippatos, TD | 1 |
1 review(s) available for pyrazines and 2-piperidone
| Article | Year |
|---|---|
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin | 2014 |
1 trial(s) available for pyrazines and 2-piperidone
| Article | Year |
|---|---|
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Topics: Adolescent; Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrazines; Pyrimidines; Republic of Korea; Risk Reduction Behavior; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
7 other study(ies) available for pyrazines and 2-piperidone
| Article | Year |
|---|---|
5-HT receptor subtypes involved in the anxiogenic-like action and associated Fos response of acute fluoxetine treatment in rats.
Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; Escape Reaction; Fluoxetine; Indoles; Locus Coeruleus; Male; Oxazines; Piperazines; Piperidones; Proto-Oncogene Proteins c-fos; Pyrazines; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists; Spiro Compounds | 2006 |
Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Breast Neoplasms; Carboxypeptidases; Cell Line, Tumor; Disease Models, Animal; Female; Gene Expression Regulation, Enzymologic; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Microarray Analysis; Multiple Myeloma; Piperidones; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Suppressor Protein p53; Ubiquitin; Ubiquitin Thiolesterase; Ubiquitination | 2011 |
Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes.
Topics: Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Boronic Acids; Bortezomib; Breast Neoplasms; Catalytic Domain; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Chalcone; Cyclin D1; Cysteine; Dose-Response Relationship, Drug; Endopeptidases; Female; HeLa Cells; Humans; Ovarian Neoplasms; Phenotype; Piperidones; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Ubiquitin Thiolesterase; Ubiquitins | 2012 |
Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress.
Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Gene Expression Profiling; Humans; Oxidative Stress; Piperidones; Polymerase Chain Reaction; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Reactive Oxygen Species; Transcription, Genetic; Ubiquitin-Specific Proteases | 2014 |
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Multiple Myeloma; Piperidones; Protease Inhibitors; Pyrazines; Ubiquitin Thiolesterase; Up-Regulation | 2014 |
A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Endoplasmic Reticulum Stress; Female; Genes, p53; Humans; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Piperidones; Proteasome Inhibitors; Pyrazines; Ubiquitination | 2013 |
Design, synthesis and biological evaluation of novel aminomethyl-piperidones based DPP-IV inhibitors.
Topics: Animals; Catalytic Domain; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Enzyme Activation; Hypoglycemic Agents; Inhibitory Concentration 50; Male; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Piperidones; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |